Premium
Current concepts in cyclooxygenase inhibition in breast cancer
Author(s) -
SinghRanger G.,
Mokbel K.
Publication year - 2002
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.1365-2710.2002.00435.x
Subject(s) - cyclooxygenase , tolerability , breast cancer , medicine , context (archaeology) , disease , cancer , population , oncology , pharmacology , adverse effect , biology , enzyme , paleontology , biochemistry , environmental health
Summary The prospect that simple medications such as non‐steroidal anti‐inflammatory drugs (NSAIDs) could be recruited into the physician's armamentarium of anticancer drugs is intriguing, especially in the context of breast cancer, one of the leading causes of mortality in the Western world. There has consequently been a wider exploration of the role of cyclooxygenase (COX) in breast cancer, and we now accept that COX‐2, one of its isoenzymes, is clearly implicated in the pathogenesis of the disease. This would seem to translate into a viable role for cyclooxygenase inhibitors in the treatment and prevention of breast cancer, but also raises issues regarding safety and tolerability of these drugs. In this article we discuss the theoretical consequences of cyclooxygenase inhibition, the significance of findings from experimental studies, large scale epidermiological investigations, and the relevance of large population studies of COX‐2 inhibitors such as CLASS and VIGOR.